Masimo starts public life with sharp rise:
This article was originally published in Clinica
Pulse oximetry company Masimo has closed its initial public offering of around 12 million shares and began life on the Nasdaq on August 8. The Irvine, California-based firm saw its share price increase by 9% on the first day of trading to $20.90 per share from $19 per share. The company has sustained this high rise since, as shares were priced at $21 at the close of markets on August 13. Masimo intends to use proceeds from the IPO to further commercialisation of its Masimo SET and Masimo Rainbow SET products - monitoring technologies which the company claims are proven to allow clinicians to accurately monitor blood oxygen saturation in critical situations by clinical and laboratory studies.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.